1. Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial. (14th October 2021) Authors: Neuen, B L; Oshima, M; Perkovic, V; Arnott, C; Bakris, G; Cannon, C P; Charytan, D M; Jardine, M; Levin, A; Neal, B; Pollock, C; Wheeler, D C; Mahaffey, K W; Heerspink, H J L Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗